Phosphorylated ERK (pERK) as biomarker in patients with advanced pancreatic cancer treated with erlotinib within a randomized phase III trial (AIO-PK0104).
Year: 2013
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Stefan Hubert Boeck, Steffen Ormanns, Ruediger Paul Laubender, Andreas Jung, Jens T Siveke, Michael Haas, Jens Neumann, Ursula Vehling-Kaiser, Cornelia Winkelmann, Ludwig Fischer von Weikersthal, Michael R. Clemens, Thomas C. Gauler, Angela Marten, Stefan Klein, Georgi Kojouharoff, Michael Geissler, Tim F Greten, Thomas Kirchner, Volker Heinemann
Institutions: LMU Klinikum, Ludwig-Maximilians-Universität München, TUM Klinikum, Technical University of Munich, Klinikum St. Marien Amberg, University of Duisburg-Essen, Heidelberg University, National Center for Tumor Diseases, Bayreuth Medical Center, Klinikum Esslingen, Medizinische Hochschule Hannover
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2591195367